MiRXES

MiRXES is rated 3 out of 5 in the category medical devices. Read and write reviews about MiRXES. MiRXES is a homegrown biotech startup based in Singapore that harnesses our world-leading microRNA technology and discoveries to deliver revolutionary biotech applications across the medical, pharmaceutical, and agricultural industries. Through our pioneering microRNA biomarker profiling efforts, we Discover new biology and biomarkers, Develop revolutionary applicative uses, and use them to Diagnose diseases early. MiRXES has commercialized a range of over 1000 life science research use products, and 2 in vitro diagnostic (IVD) products approved by Singapore's Health Sciences Authority (HSA): a microRNA-based blood test for early detection of stomach cancer (GASTROClear) and the A*STAR Fortitude 2 SARS-CoV-2 diagnostic test. We are committed to building a global microRNA-based ecosystem in collaboration with a strong network of clinicians, researchers, and corporates to translate microRNA research into clinical products and biotech solutions that are affordable, accurate, and accessible. Our innovation help transform healthcare, improve and save lives, while balancing our commercial responsibilities. We focus on the business areas of Life Science Research Products (LS), in vitro Diagnostics (IVD), and as a Contract Development and Manufacturing Organisation (CDMO). These business areas are supported by our core Research and Development (R&D) and ISO13485-certified manufacturing. MiRXES' core technology platform is based on our patented real time RT-PCR and know-how accumulated from over 10 years of translational microRNA research and profiling over 50,000 clinical samples from over 20 different diseases.